Science Exchange Announces Outsourced R&D Collaboration with UC Davis Venture Catalyst Group

February 12, 2018 | Posted by Team in Press Release |

Science Exchange Venture Catalyst Collaboration

Palo Alto, CA – February 12, 2018 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced a strategic collaboration with Venture Catalyst, a unit within the Technology Management and Corporate Relations division of the UC Davis Office of Research which supports the development of new ventures fueled by university research.

Science Exchange will provide entrepreneurs and startups participating in the Venture Catalyst Smart Toolkit for Accelerated Research Translation (START™) Program immediate access to the private R&D marketplace with dedicated PhD-level sourcing support around the clock and a special contracting structure to accelerate their research and development projects.

“The Science Exchange platform solves the challenges of R&D outsourcing by providing scientists with on-demand access to a diverse network of prequalified external providers under a single relationship while also providing sourcing departments with more information and control over their outsourcing spending,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are thrilled to be collaborating with Venture Catalyst to offer a customized R&D marketplace and help its portfolio of companies complete their research and clinical projects more quickly and efficiently. It’s clear that Venture Catalyst is supporting companies with extremely promising technologies in development, and we’re honored to help get their discoveries to market faster.”

With this collaboration, Science Exchange will support client-specific governance, approval workflows, and preferred vendors, all the while enabling instant access to research services and custom products from 2,500 providers in over 6,000 research areas. To help external service providers minimize the risk frequently associated with outsourcing,  Science Exchange’s guarantee ensures complete protection of data, assets and performance of agreed-upon services, all backed by the best-in-class, SOC 2-compliant information technology security infrastructure. Science Exchange’s ISO 9001-certified quality assurance system and dedicated regulatory compliance team also support regulated outsourced work.

Venture Catalyst is the latest innovation and startup support organization to choose to partner with Science Exchange. They now join more than 30 enterprise organizations including most of the top 20 biopharma companies that use Science Exchange to more efficiently manage outsourced R&D.

“Science Exchange offers a unique platform for our startups to connect with a broad network of qualified scientific providers,” said Dushyant Pathak, Associate Vice Chancellor of Research and Executive Director of Venture Catalyst at UC Davis. “We anticipate that working with Science Exchange through the START Program will enable us to commercially advance the discoveries made by Venture Catalyst-supported startups and early-stage companies, in areas as diverse as biomedical and life sciences, agriculture and animal health, and physical sciences and engineering.”

 

About Venture Catalyst

Venture Catalyst furthers the University’s educational, research and public mission by supporting UC Davis students, faculty and researchers in translating science, engineering and innovative research through well-resourced startups, into societal impact.  Venture Catalyst engages collaboratively with internal and external drivers of innovation and works closely with the University’s Institute for Innovation & Entrepreneurship.  In addition to its Smart Toolkit for Accelerated Research Translation (START™) program, Science Translation and Innovative Research (STAIR™) Proof-of-Concept grants, Venture Catalyst supports a network of regional technology startup incubators through its Distributed Research Incubation & Venture Engine (DRIVE™) Network.

Novaseek Research Partners with Science Exchange to Broaden Access to Its CDNR Platform for Biomedical and Clinical Research

February 5, 2018 | Posted by Team in Drug Discovery, New Innovations, Press Release, Research |

 

PALO ALTO, Calif., DATE – Science Exchange, the world’s leading enterprise platform for outsourced research and development services and acquisition of human biospecimens, announced today its partnership with Novaseek Research Inc., a health information technology for life sciences company.

Now thousands of researchers using Science Exchange have on-demand access to Novaseek’s Clinical Data Network for Research (CDNR) platform to procure biospecimens, with patient consent and authorization, and associated real-world clinical data in pursuit of accelerating medical innovation. Researchers can utilize the CDNR platform in support of discovery, translational medicine, observational and clinical studies while Science Exchange manages the contracting process and tracks analytics to report performance and process improvement.

“Our CDNR platform can help accelerate the long and costly research process by precisely identifying patient populations with highly specific characteristics, starting early in the development process and continuing throughout,” said Andrei Soran, CEO of Novaseek Research. “Our partnership with Science Exchange enables clinical researchers to focus on getting medicines to market faster while Science Exchange provides operational and service support.”

“The fastest path to novel platforms like Novaseek’s CDNR via Science Exchange helps our leading biopharma clients to accelerate the drug development process and get important medicines to market quickly,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are committed to including the best scientific providers on our platform, and Novaseek meets our stringent vetting criteria. By leveraging population analytics, they help streamline study design and free scientists to focus on innovation.”

About Novaseek

Novaseek Research, Inc. is a game-changing health IT for life sciences company that provides turn-key, dynamic access to real world clinical data and biospecimens from a network of healthcare organizations. We envision a world where a clear understanding of real-world patients is central to every stage of life sciences research and drug development. For more information, please visit  www.novaseekresearch.com.

About CDNR

Novaseek’s award-winning, novel, cloud platform, the Clinical Data Network for Research (CDNR), easily interfaces with hospital data sources in real time. The CDNR enables researchers to define patient cohorts through population analytics and to access consented biospecimens and clinical data to advance translational medicine, clinical development and observational studies. CDNR enables the fulfillment of complex requests, such as the collection of biospecimens and data before and after specific treatments, without burdening patients with extra blood draws or extensive medical questionnaires. This approach allows more hospitals and patients to participate in supporting biomedical research.

 

Talk to the Novaseek team today about your biospecimen and clinical data needs — visit their storefront and request a quote with your Scope of Work.

Rapid Novor Inc. Launches REmAb™ Antibody Protein Sequencing Services on Science Exchange

January 24, 2018 | Posted by Team in Drug Discovery, New Innovations, Press Release, Research |

PALO ALTO, CA, January 25, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced a partnership with Rapid Novor Inc to offer its REmAb™ Antibody Protein Sequencing Services to scientists around the world using Science Exchange’s R&D platform.

Rapid Novor, Inc. is a Kitchener-Waterloo (Canada)-based CRO dedicated to the development of antibody protein sequencing technologies. The company’s mission is to advance life science research to better human health with next-generation protein sequencing. With the opening of its own state-of-the-art mass spectrometry lab in 2017, the team has successfully sequenced hundreds of monoclonal antibodies directly from the proteins and helped pharmaceutical companies in their antibody drug discovery.

“Our focus is on the development of antibody protein sequencing technologies, and we are the only team that has both a mass spectrometry lab and proprietary sequencing software platform,” said Mingjie Xie, Co-founder and CEO of Rapid Novor, Inc. “We are uniquely positioned to offer superior protein sequencing services to researchers worldwide. The partnership with Science Exchange will allow us to provide easy-to-access services to enterprise biopharma companies and offer them cutting-edge technologies in a seamless manner.”

“We are thrilled to partner with Rapid Novor Inc to make its REmAb™ Antibody Protein Sequencing Services available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “By partnering with the leading CROs in different research and technology sectors, we are bringing in the best and brightest service providers to our secure and readily available platform so that the scientists can focus on developing breakthrough discoveries. Having Rapid Novor Inc as part of our supplier portfolios is an example of our commitment to making it easy for researchers to access the world’s leading scientific service providers and most innovative scientific technologies.”

About Rapid Novor, Inc.

Rapid Novor, Inc. is the world’s leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence the antibody proteins without needs to access the cell line. As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company’s REmAb™ antibody protein sequencing service has allowed the accurate sequencing of any given antibody proteins routinely. The company’s WILD™ service is the first commercially available service that can accurately distinguish the isomeric isoleucine and leucine using mass spectrometry. For more information, visit www.rapidnovor.com. Follow the company on Twitter @rapidnovor.

Nanome Partners with Science Exchange to Offer Virtual Reality Drug Design Tools and Blockchain Solutions to Scientists

January 18, 2018 | Posted by Team in Drug Discovery, New Innovations, Press Release |

Nanome Partners with Science Exchange

PALO ALTO, CA, January 18, 2018 Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced a partnership with Nanome Inc. to offer scientists on-demand access to Nanome’s blockchain and virtual reality technology.

Nanome is a San Diego-based company whose mission is to democratize science through blockchain technology and virtual reality tools to aid in the progression of molecular precision and advancements in nanotechnology.

“We can revolutionize the way science is done through our virtual reality drug design tool, NanoPro, and the Matryx blockchain platform,” said Steve McCloskey, CEO and Founder of Nanome. “Historically, scientists have had problems with collaboration and efficiency in their research, so we are excited to partner with Science Exchange to accelerate scientific development across the world.”

“We are thrilled to welcome Nanome to Science Exchange’s platform of more than 2,500 qualified providers that allow researchers access to innovative scientific technologies and services to advance their discoveries,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Our global community of scientists can now instantly access Nanome’s virtual reality drug design and development tool to better visualize complex 3D data through immersive applications.”

About Nanome

Nanome primarily helps medicinal chemists and structural biologists understand complex molecular data through immersive and collaborative applications that facilitate faster pattern recognition, better molecular visualization, and a more efficient drug design and drug discovery process. The Matryx blockchain platform enables researchers to collaborate and share results while securing their intellectual property through the blockchain.

Science Exchange Partners with Lab Launch to Help its Startups Advance Scientific Innovations

January 10, 2018 | Posted by Team in Press Release |

Lab Launch Science Exchange Enterprise Outsourcing PlatformPalo Alto, CA – January 10, 2018 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), teamed up today with Lab Launch, a nonprofit working to provide affordable and high-quality laboratories to biotech startups. This partnership with Science Exchange allows Lab Launch’s resident companies to easily supplement and complement their in-house resources with external research tools, technologies, and expertise.

Science Exchange enables immediate access to over 2,500+ commercial CROs, academic labs, and government facilities under a single marketplace agreement, in addition to a 24/7 PhD-level support by Science Exchange staff scientists.

“Our goal is to give LA-based scientists and entrepreneurs every opportunity to further their ideas and innovations in a way that is affordable and that will also give them access to the best scientific resources available,” said Marie Rippen, CEO of Lab Launch.  “By partnering with Science Exchange, Lab Launch can now offer our companies access to fully vetted service providers in a secure environment, so our scientists can devote time to advancing their ideas instead of being bogged down with administrative tasks including researching and negotiating with service providers.”

“Lab Launch and Science Exchange are both driven to give scientists the tools and support they need to be successful in developing their breakthrough ideas,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Scientists at Lab Launch will now automatically gain access to the best scientific providers to help bring groundbreaking discoveries to market. We are excited to be part of the process!”

Lab Launch is the latest R&D organization to choose to partner with Science Exchange and joins more than 30 enterprise clients and Life Science incubators that are effectively managing their outsourced R&D with Science Exchange-powered marketplaces.

About Lab Launch

Lab Launch Inc is a 501(c)(3) non-profit working to establish a more dynamic biotech startup environment in Los Angeles. Our mission is to enable LA’s scientists and entrepreneurs to develop their ideas in affordable, high-quality lab facilities, with access to services and a supportive innovation community to accelerate their success.

 

Request a demo of Science Exchange’s platform to see how your organization can benefit from increased access to innovation and organizational efficiency.

Breakout Labs Partners with Science Exchange to Empower its Portfolio Companies with External Research Innovations

December 18, 2017 | Posted by Team in New Innovations, Press Release, Science Exchange News |

Breakout Labs Science Exchange

Palo Alto, CA – December 18, 2017 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced a strategic partnership with Breakout Labs, a fund within the Thiel Foundation that backs scientist-entrepreneurs working at the intersections of technology, biology, materials, and energy. The newly formed partnership allows for Breakout Labs to provide its portfolio companies’ scientists with on-demand access to a global network of research suppliers via the Science Exchange-powered private marketplace.

The private marketplace enables instant access to thousands of research tools, technologies, and services from over 2,500+ commercial CROs, academic labs, and government facilities under a single Science Exchange contract. Additionally, the platform users receive end-to-end PhD-level support from the Science Exchange staff scientists in identifying the best external innovations to expedite their R&D cycles.

“Our companies are small innovative startups that, despite being cash-constrained, are at the forefront of radical scientific breakthroughs,” said Hemai Parthasarathy, Scientific Director of Breakout Labs.  “Science Exchange’s marketplace helps these companies adopt virtualization in their R&D process and give them an opportunity to access external resources they need to bring their innovations to market. Science Exchange fits into the ethos that prompted the formation of Breakout Labs by removing barriers for startups to access scientific services that will help accelerate their discoveries.”

“At Science Exchange, we are passionate about accelerating discovery by making connections — in this case, vital connections between scientist-entrepreneurs and experienced providers of scientific products and services,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Through this partnership, the scientists at Breakout Labs’ companies, can now focus on what they do best, bringing game-changing scientific discoveries to market, and rely on us to find the best scientific providers to help them accomplish that.”

Breakout Labs is the latest R&D organization to choose to partner with Science Exchange and join more than 30 enterprise clients and Life Science incubators that are effectively managing their outsourced R&D with Science Exchange-powered marketplaces.

About Breakout Labs

Breakout Labs is a revolving fund within the Thiel Foundation that supports early stage companies as they transition radical scientific advances out of the research lab and into the economy. The program backs bold scientists who work at the intersections of technology, biology, materials, and energy. More than capital, Breakout Labs provides additional support through a two-year program that includes introductions to follow-on funders, corporate partners and other resources to drive commercialization. To learn more, visit: www.breakoutlabs.org.

Bioinformatics Solutions, Inc. Chooses Science Exchange as the Primary Online Channel to Offer Protein de novo Sequencing Services to Scientists

December 11, 2017 | Posted by Team in Lab Profiles, New Innovations, Press Release, Research |

BSI Science Exchange Partnership

PALO ALTO, CA, December 11, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced the partnership with Bioinformatics Solutions, Inc. to offer online access to its protein de novo sequencing services to scientists around the globe.

As the creators of the well-known, highly established PEAKS Software, the golden standard of de novo sequencing, Bioinformatics Solutions, Inc., offers their de novo sequencing expertise to scientists at a new level by sequencing the samples themselves.

“Bioinformatics Solutions, Inc. has developed a proprietary de novo protein sequencing workflow to retrieve the amino acid sequence of an unknown antibody protein with state-of-the-art mass spectrometry techniques. Through this workflow, the sequence assembly is purely based on de novo sequencing. Therefore, no database, cDNA, mRNA, or hybridoma cell line is required,” exclaims Baozhen Shan, CEO of Bioinformatics Solutions, Inc. “With constant ongoing research at Bioinformatics Solutions, Inc., the advanced technology will ensure our service delivers a highly accurate sequence, identification of sequence variants, glycosylations, and unknown modifications.  By partnering with Science Exchange, these sequencing services will now be available to researchers all over the world to help them make breakthrough discoveries.”

Over the last few years, Science Exchange has undergone extensive growth and recently received a $28 million in Series C funding led by Norwest Venture Partners. By continuing to team up with companies like Bioinformatics Solutions, Inc. Science Exchange is providing researchers worldwide with access to the most important scientific services to advance their experiments.

“We are excited to partner with Bioinformatics Solutions, Inc. to make available its protein de novo sequencing services to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange.  “Science Exchange is committed to adding the most innovative and qualified service providers to our platform, so scientists have the services they need securely and readily available to aid their discoveries. Bioinformatics Solutions, Inc. met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of proteomics analysis.”

 

About Bioinformatics Solutions, Inc.

For more than 15 years, Bioinformatics Solutions, Inc. has been changing the field of proteomics analysis, by pushing the boundaries of its computational limits and striving to provide groundbreaking research with the customer-first approach. Bioinformatics Solutions, Inc. believes the only solution is one that incorporates quality and timely results, a satisfying product experience, customer support and two-way communication. This diverse and adaptable group is committed to serving the needs of pharmaceutical, biotechnological, and academic scientists; and to the progression of recombinant protein production and drug discovery research. For more information, visit www.scienceexchange.com/labs/bioinformatics-solutions-inc. Follow the company on Twitter @PEAKSProteomics and @PEAKSAB.

Science Exchange Wins Two Gold Stevie® Awards in 2017 Stevie Awards for Women in Business

November 21, 2017 | Posted by Team in Company, Press Release, Science Exchange News |

Dr. Elizabeth Iorns Honored as Female Entrepreneur of the Year and Science Exchange as Most Innovative Company of the Year

Gold Stevie Award 2017 Science Exchange

Palo Alto, CA – November 21, 2017 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced that CEO and Co-Founder Dr. Elizabeth Iorns, has been named the winner of the Gold Stevie® Award for Female Entrepreneur of the Year. In addition, Science Exchange has been named Most Innovative Company of the Year at the 14th annual Stevie Awards for Women in Business.

The Stevie Awards for Women in Business are the world’s top honors for female entrepreneurs, executives, employees and the organizations they run. The 2017 awards received over 1500 entries from 25 nations and territories; winners were recognized at a November 17 event in New York City.

Dr. Elizabeth Iorns founded Science Exchange in 2011 and has built a global company that has raised over $58M in venture funding. Dr. Iorns has led Science Exchange to rapid growth with enterprise partnerships with the most innovative R&D focused Fortune 100 companies. Science Exchange provides a technology platform for efficient access to the world’s best external R&D partners. Through Science Exchange, scientists can instantly connect and order outsourced scientific projects from over 2,500 top research facilities available under the Science Exchange contract.

“I am honored to receive the Stevie award and be recognized among other inspiring women and companies around the world,” said Dr. Elizabeth Iorns, co-founder and CEO of Science Exchange. “I am also extremely proud of the teams at Science Exchange that work tirelessly with our clients on their outsourced R&D projects to accelerate scientific discovery.”

“The judges were so impressed with the accomplishments of all of the Stevie Award-winning women and organizations. The 2017 Stevie Awards for Women in Business received a record number of nominations and had a record number of ceremony attendees,” said Michael Gallagher, founder and president of the Stevie Awards. “We congratulate all of this year’s Grand, Gold, Silver and Bronze Stevie Award winners for their achievements.”

Details about the Stevie Awards for Women in Business and the list of Stevie Award winners are available at www.StevieAwards.com/Women.  

 

Science Exchange Announces Outsourced R&D Partnership with Alector

November 20, 2017 | Posted by Team in Company, Drug Discovery, Outsourcing Best Practices, Press Release, Science Exchange News |

Science Exchange-Alector PartnershipPALO ALTO, Calif.–Science Exchange, the world’s leading and most secure enterprise platform and aggregator for outsourced research and development (R&D), today announced a strategic partnership with Alector, a biotech company pioneering the discovery & development of immuno-neurology therapies for neurodegenerative disorders, to provide the company’s scientists access to a private R&D marketplace to accelerate their research.

“The Science Exchange platform solves the challenges of R&D outsourcing: we provide scientists with efficient access to a diverse network of qualified suppliers under a single relationship, and at the same time we provide sourcing departments with more information and control over their outsourcing spend,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are thrilled to be the provider of Alector’s R&D marketplace and help bring potential treatments for Alzheimer’s disease to patients more quickly and efficiently. Especially following the exciting news on Alector’s partnership with AbbVie to advance therapies for Alzheimer’s disease, it’s clear that Alector has extremely promising drug targets — we’re honored to help accelerate these important discoveries.”

The Science Exchange-powered R&D marketplace enables scientists to instantly order more than 6,000 unique scientific services from the 2,500 CROs, academic labs, and government facilities that are available under a single Science Exchange contract. The partnership also will provide Alector with a platform to effectively manage the company’s outsourced R&D investments, including the ability to track supplier utilization, trends, and performance, which also supports the need for compliance with internal policies and external regulations.

Alector is the latest R&D company to choose to partner with Science Exchange, and joins more than 30 enterprise organizations, including 10 of the top 20 pharma companies, that use Science Exchange to more efficiently manage outsourced R&D.

“Science Exchange offers a unique platform for connecting with a broad network of qualified scientific service providers,” said Arnon Rosenthal, Ph.D., co-founder and CEO of Alector. “It is our hope that working with Science Exchange will enable us to more quickly advance discovery and development of novel immuno-neurology therapies.”

Under the agreement, Science Exchange will support company-specific governance, approval workflows, and preferred vendors. To minimize the risk frequently associated with outsourcing to external service providers, the Science Exchange guarantee ensures complete protection of data, assets and performance of agreed-upon services, all backed by a best-in-class, SOC 2-compliant information technology security infrastructure. Science Exchange’s ISO 9001-certified quality assurance system and dedicated regulatory compliance team also support regulated work.

 

Visit www.scienceexchange.com/enterprise to request a demo of our award-winning private marketplaces for managing outsourced research and development!

Elizabeth Iorns, Ph.D., CEO of Science Exchange Elected to the Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT)

November 15, 2017 | Posted by Team in Press Release |

Elizabeth Iorns elected to DCAT Board

PALO ALTO, CA, November 15, 2017 Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced today that Elizabeth Iorns, Ph.D., CEO of Science Exchange, has been elected to serve her first term on the Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT) beginning November 1, 2017.  Members of DCAT’s Board of Directors are charged with the important work of guiding the organization’s strategic initiatives and activities.

“We are delighted to have Dr. Iorns join the Board of Directors,” said DCAT Executive Director Margaret Timony. “She brings a unique mix of leadership experiences that will add a valuable perspective to the board.”

“I am honored to join the board and work together with this great team to address key initiatives related to the pharmaceutical industry,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Our mission at Science Exchange is to help accelerate innovation and scientific discoveries, and as a scientist myself, I feel joining DCAT’s board is a perfect opportunity for me to share my ideas and insights to support and advance its programs and services.”

About DCAT

The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.

 

Explore Science Exchange’s network of qualified service providers for:

 

 

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com